MedTrace Logo

Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome

NCT00551343 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-07-07

No results posted yet for this study

Summary

The purpose of this study is to investigate the effects of a GLP-1 agonist on satiety hormones in patients with Prader-Willi Syndrome (genetic defect causing obesity).

Conditions

Interventions

DRUG

Exenatide

10ug Exenatide single s.c. injection

Sponsors & Collaborators

  • Garvan Institute of Medical Research

    lead OTHER

Principal Investigators

  • Lesley V Campbell, Prof · Garvan Institute of Medical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00551343 on ClinicalTrials.gov